Cerebrolysin

Research Papers and Clinical Trials

Recent research on Cerebrolysin has focused primarily on its neuroprotective effects across various neurological conditions, though several concerning retractions limit the available evidence base.

Key Clinical Studies

A 6-month prospective cohort study examined Cerebrolysin's neuroprotective effects in patients with moderate traumatic brain injury who had nonoperative lesions. This observational study suggests potential benefits, though the specific sample size and detailed outcomes are not provided in the available evidence.

A systematic review and meta-analysis published in Brain and Behavior (2026) evaluated Cerebrolysin as an adjunct to mechanical thrombectomy in acute ischemic stroke patients. This analysis focused specifically on observational studies, indicating that randomized controlled trial evidence may be limited for this application.

Mechanistic Research

Laboratory research has explored Cerebrolysin's cellular mechanisms, including a study on exosomes released by Cerebrolysin-treated cerebral endothelial cells and their effects on blood-brain barrier permeability. Additional basic science work examined its effects in snail models of learning and memory, though the clinical relevance of these findings remains unclear.

Clinical Trials

Several clinical trials are registered but provide limited outcome data:

• A Phase 4 completed trial (NCT01996761) studied motor recovery effects in subacute stroke patients
• A Phase 1/2 recruiting trial (NCT05821075) is comparing Cerebrolysin to prednisolone for Bell's palsy treatment
• Additional trials have examined applications ranging from COVID-19-related smell/taste loss to hair repigmentation

Important Limitations

Multiple retractions significantly impact the evidence base. At least three papers have been retracted from major journals (Neurochemical Research, Journal of Alzheimer's Disease, and Molecular Neurobiology), including studies on neuropathic pain, Alzheimer's disease, and Parkinson's disease applications.

The available evidence is largely observational, with limited high-quality randomized controlled trial data. Many registered trials lack published results, making it difficult to assess efficacy across different neurological conditions.

This information is for educational purposes only and should not replace professional medical advice. Consult healthcare providers for treatment decisions.